pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

General Medicine secures $120 million to launch all-in-one healthcare marketplace

Oct 8, 2026·read at Endpoints ↗DealPositive

General Medicine, a health‑tech startup, announced it has raised $120 million in a financing round.

The capital will be used to develop a digital platform that functions as a one‑stop shop for medical products and services, blending AI tools with human assistance.

The move follows a trend of similar companies such as Hims and Ro offering broad health‑care solutions, and investors see the model as a way to simplify consumer access.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “General Medicine raises $120M to build a healthcare store that offers everything”

read at Endpoints ↗
97 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 33m agoOno pays Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya shotEndpoints
  • 33m agoEndeavor notches major mid-stage trial win, says IPF drug can reverse diseaseEndpoints
  • 50m agoLong ignored by drugmakers, preeclampsia is now a focus for WHO and biopharmaEndpoints
  • 1h agoGrindr's big bet on telehealthEndpoints
  • 1h agoZealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacleEndpoints